Arthrosilen, capsules 320 mg 10 pcs

It has anti-inflammatory, analgesic and antipyretic effects. By inhibiting COX-1 and -2 it inhibits the synthesis of PG. It has anti-bradykinin activity, stabilizes lysosomal membranes and inhibits release of enzymes from them that contribute to tissue destruction in chronic inflammation.

Decreases release of cytokines, inhibits neutrophil activity.

Limits morning stiffness and swollen joints and increases range of motion.

Ketoprofen lysine salt, unlike ketoprofen, is a rapidly soluble molecule with a neutral pH and is almost non-irritating to the gastrointestinal tract.

When used topically, it has a local anti-inflammatory, anti-exudative and analgesic effect.

In the form of a spray or gel it provides local therapeutic effect on affected joints, tendons, ligaments and muscles.

In joint syndrome, it relieves joint pain at rest and on movement, reduces morning stiffness and joint swelling. The lysine salt of ketoprofen has no catabolic effect on articular cartilage.

Indications

Active ingredient

Composition

1 capsule contains ketoprofen lysine salt 320 mg

How to take, the dosage

1 capsules a day with or after meals.

The duration of treatment may be 3-4 months.

Interaction

Inducers of microsomal oxidation in the liver (phenytoin, ethanol, barbiturates, flumecinol, rifampicin, phenylbutazone, tricyclic antidepressants) in concurrent use with the drug Arthrozilen increase metabolism of ketoprofen (increase the production of hydroxylated active metabolites).

With the simultaneous use of the preparation Artrozilen the effectiveness of uricosuric drugs decreases, the effect of anticoagulants, antiaggregants, fibrinolytics, ethanol, the side effects of mineralocorticoids, glucocorticoids, estrogens; the effectiveness of antihypertensive drugs and diuretics decreases.

The simultaneous use of the drug Artrosilen with other NSAIDs, GCS, ethanol, corticotropin may lead to ulceration and gastrointestinal bleeding, and increased risk of renal dysfunction.

The simultaneous administration of Artrosilen with oral anticoagulants, heparin, thrombolytics, antiaggregants, cefoperazone, cefamandole and cefotetan increases the risk of bleeding.

The drug Artrosilen when used concomitantly increases the hypoglycemic effect of insulin and oral hypoglycemic drugs (recalculation of the dose is necessary).

The co-administration of Artrozilen with sodium valproate causes platelet aggregation disorders.

Ketoprofen when used concomitantly increases the plasma concentration of verapamil and nifedipine, lithium, methotrexate.

Antacids and colestiramine decrease the absorption of ketoprofen when concomitant use with the drug Arthrozilen.

Special Instructions

The peripheral blood count and the functional state of the liver and kidneys should be monitored during treatment.

If it is necessary to determine 17-ketosteroids, the drug should be discontinued 48 hours before the study.

The administration of ketoprofen may mask signs of infectious disease.

In case of impaired renal and hepatic function, dose reduction and close monitoring are necessary.

The use of ketoprofen by patients with bronchial asthma may lead to an attack of bronchial asthma.

Women who are planning to become pregnant should refrain from using the drug because the likelihood of implantation of an egg may be reduced.

Impact on driving and operating machinery

When using the drug, refrain from potentially hazardous activities requiring increased concentration and quick psychomotor reactions.

Contraindications

Side effects

Gastrointestinal organs: abdominal pain, diarrhea, stomatitis, esophagitis, gastritis, duodenitis, erosive gastrointestinal ulcers, hematomeisis, melena.

Hepatic system disorders: increased bilirubin level, increased liver enzyme activity, hepatitis, liver failure, increased liver size.

Nervous system disorders: dizziness, hyperkinesia, tremor, vertigo, mood swings, anxiety, hallucinations, irritability, general malaise.

Sensory organs: conjunctivitis, visual impairment.

Skin disorders: urticaria, angioedema, erythematous exanthema, pruritus, maculopapular exanthema, increased sweating, erythema multiforme (including Stevens-Johnson syndrome).

Urogenital system disorders: painful urination, cystitis, edema, hematuria, menstrual disorders.

Hematopoietic disorders: leukocytopenia, leukocytosis, lymphangitis, decreased PV, thrombocytopenia, thrombocytopenic purpura, increased spleen size, vasculitis.

Respiratory system: bronchospasm, dyspnea, sensation of laryngeal spasm, laryngospasm, laryngeal edema, rhinitis.

Cardiovascular system: hypertension, hypotension, tachycardia, chest pain, syncope, peripheral edema, paleness.

Allergic reactions: anaphylactoid reactions, oral mucosal edema, pharyngeal edema, periorbital edema.

Overdose

There are currently no reported cases of overdose with Arthrosilen.

Pregnancy use

Like other NSAIDs, Arthrosilen should not be used in the third trimester of pregnancy.

The use of the drug in I and II trimesters should be carefully controlled by the attending physician.

Breast-feeding should be discontinued when using the drug.

It is contraindicated in children under 18 years of age.

Similarities